前端編輯

管理員身份可於登入後,進行網站的前端管理。

 

·        連絡電話:07-312-1101 ext.5092 #34

·        電子信箱:mrpan@cc.kmu.edu.tw; pan.meiren0324@gmail.com

·        辦公位置:國際學術研究大樓4樓研究室

 

 PAN

 

專長

癌細胞轉移;淋巴血管新生;癌細胞抗藥性機制;基因突變修復機制

研究方向

腫瘤的多樣性一直是造成治療成效上的瓶頸。因此,個人化的治療是近年來不論是臨床醫學或基礎研究一直著力發展及探討的主軸。本實驗室研究方向著重在探討癌細胞轉移及血管新生的分子機制。想藉由其中了解,進而研發具有專一性的標的以用來做為臨床診斷上的工具及藥物的開發。

除此之外,抗藥性細胞株的產生是造成臨床上治療失敗的原因。為了有效改善病人用藥的效果進而提升病人的存活率,以期許能做為個人化治療的方針。近年來,我們實驗室利用基因體學和蛋白質體學分析技術來試圖找出新特定蛋白表現與藥物或放射線治療成效的相關性。我們發現,表異質基因調控酵素(Epigenetic modification enzymes)對於癌細胞轉移和抗藥性細胞株產生扮演重要角色。已知癌細胞惡性化的表徵與癌幹細胞有著密不可分的關係存在。因此,本實驗室特別就針對表異質基因調控酵素與癌細胞轉移、抗藥性細胞株產生及幹細胞特性做為研究主軸。希望此研究方向不僅可以找出針對癌症幹細胞的新穎治療藥物,也有助於臨床上診斷,以有效解決臨床醫學所面臨的問題。

學歷

高雄醫學大學醫學研究所博士

經歷

·        MD Anderson Cancer Ctr., Houston, TX 博士後研究員 (2008-2011)

·        國家衛生研究院癌症研究所 博士後研究員 (2011-2013)

·        高雄醫學大學臨床醫學研究所 助理教授(2013~2018

          ·     高雄醫學大學臨床醫學研究所教授(2018~

 

代表著作

                          

1.          Luo CW, Wu CC, Chang SJ, Chang TM, Chen TY, Chai CY, Chang CL, Hou MF, Pan MR. CD4-mediated loss of E-cadherin determines metastatic ability in triple-negative breast cancer cells.Experimental Cell Research. 2018 Feb 1;363(1):65-72.

2.          Pan MR, Hsu MC, Chen LT, Hung WC. Orchestration of H3K27 methylation: mechanisms and therapeutic implication. Cellular and Molecular Life Sciences. 2018 Jan;75(2):209-223.

3.          Hou MF, Luo CW, Chang TM, Hung WC, Chen TY, Tsai YL, Chai CY, Pan MR The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer. Experimental Cell Research. 2017 Oct 15;359(2):458-465.

4.          Wu CC, Pan MR, Wei YC, Lin CH, Yang SF, Tsai HP, Luo CW, Chai CY. CHD4 as a potential biomarker in differentiating between cellular schwannoma and malignant peripheral nerve sheath tumor. Applied Immunohistochemistry & Molecular Morphology doi: 10.1097/PAI.0000000000000522.

5.          Luo CW, Wang JY, Hung WC, Peng Guang, Tsai YL, Chang TM, Chai CY, Lin CH and Pan MR. G9a governs colon cancer stem cell phenotype and chemoradioresistance through PP2A-RPA axis-mediated DNA damage response. Radiotherapy and Oncology. 2017 Sep;124(3):395-402.

6.          Yin HL,Wu CC, Lin CH, Chai CY, Hou MF, Chang SJ, Tsai HP, Hung WC, Pan MR# and Luo CW. Beta1 Integrin as a Prognostic and Predictive Marker in Triple-Negative Breast Cancer. International Journal of Molecular Sciences 2016 Aug 31;17(9). pii: E1432. (#co-corresponder).

7.          Pan MR, Hsu MC, Chen LT, Shen YS, Hung WC. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. Oncotarget 2016 Sep 20;7(38):61136-61151.

8.          Pan MR, Li Kaiyi, Lin SY and Hung WC. Connecting the Dots: From DNA Damage and Repair to Aging. International Journal of Molecular Sciences. 2016 May 6;17(5).

9.          Pan MR, Hsu MC, Liu JY, Chen LT, Hung WC. G9a orchestrates PCL3 and KDM7A to promote histone H3K27 methylation. Scientific Reports. 2015 Dec 21;5:18709.

10.      Leu MH, Huang CC, Pan MR*, Chen HH, Hung WC (2012). Prospero homeobox 1 promotes epithelial-mesenchymal transition in colon cancer cells by inhibiting E-cadherin via miR-9. Clinical Cancer Research 18(23): 6416-25 (*co-first author).

11.      Chuang CW, Pan MR*, Hou MF, Hung WC (2012). Cyclooxygenase-2 up-regulates CCR7 expression via AKT-mediated phosphorylation and activation of Sp1 in breast cancer cells. Journal of Cellular Physiology 228(2): 341-8. (*co-first author).

12.      Peng G, Dai H, Zhang W, Hsieh HJ, Pan MR, Park YY, Tsai RY, Bedrosian I, Lee JS, Ira G, Lin SY (2012). Human Nuclease/Helicase DNA2 Alleviates Replication Stress by Promoting DNA End Resection. Cancer Research 72(11): 2802-13.

13.      10. Pan MR, Hsieh HJ, Dai H, Hung WC, Li K, Peng G, Lin SY (2012). Chromodomain helicase DNA-binding protein 4 (CHD4) regulates homologous recombination DNA repair and its deficiency sensitizes cells to poly (ADP-ribose) polymerase (PARP) inhibitor Treatment. The Journal of Biological Chemistry 287 (9): 6764-72.

14.       Pan MR, Peng G, Hung WC, Lin SY (2011). Monoubiquitination of H2AX regulates DNA damage  response signaling. The Journal of Biological Chemistry 286(32): 28599-607.

15.      Pan MR, Chang TM, Chang HC, Su JL, Wang HW, Hung WC (2009). Sumoylation of Prox1 controls  its ability to induce VEGFR3 expression and lymphatic phenotypes in endothelial cells. Journal of Cell Science 122 (Pt 18): 3358-64.

16.      Peng G, Yim EK, Dai H, Jackson AP, Burgt I, Pan MR, Hu R, Li K, Lin SY (2009). BRIT1/MCPH1 links chromatin remodeling to DNA damage response. Nature Cell Biology 11 (7): 865-72.

17.      Pan MR, Chang HC, Wu YC, Huang CC, and Hung WC (2009). Tubocapsanolide A inhibits transforming growth factor-beta                       activating kinase 1(TAK1) to suppress NF-kappaB-induced CCR7. The Journal of Biological Chemistry 284 (5): 2746-54.

18.      Pan MR, Hou MF, Chang HC, Hung WC (2008). Cyclooxygenase-2 up-regulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. The Journal of Biological Chemistry 283 (17): 11155-63

19.      1Pan MR, Chang HC and Hung WC (2008) Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras/c-Raf interaction and activation of MAP kinase phosphatases. Cellular Signaling 20 (6): 1134-41.

20.      Pan MR, Hung WC (2008) The non-steroidal anti-inflammatory drug NS398 reactivates SPARC expression via promoter demethylation to attenuate invasiveness of lung cancer cells. Experimental Biology and Medicine 233 (4): 456-62.

21.       Chang HC, Chang FR, Wang YC, Pan MR, Hung WC, Wu YC (2007) A bioactive withanolide Tubocapsanolide A inhibits proliferation of human lung cancer cells via repressing Skp2 expression. Molecular Cancer Therapetics 6(5): 1572-8.

22.      Pan MR, Hung WC (2002) Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. The Journal of Biological Chemistry 277(36): 32775-80.

23.      Pan MR, Chuang LY, Hung WC (2001) Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Letter 508(3): 365-8.

24.      Hung WC, Chang HC, Pan MR, Lee TH, Chuang LY (2000) Induction of p27 (KIP1) as a mechanism  underlying NS398-induced growth inhibition in human lung cancer cells. Molecular Pharmacology  58(6): 1398-403.

 

Go to top